Flagship Pioneering, LLC Long-Term Concentrated

CIK: 0001400240 · Show all filings

Period: Q4 2019 (← Previous) (Next →)

Filing Date: Feb 13, 2020

Total Value ($000): $1,788,867 (100.0% shares, 0.0% debt)

Holdings (8)

MRNA Moderna Inc 55.6%

Value ($000) $995,047 Shares 50,871,524 Est. Cost $16.43 Unrealized +7.9%

— Rubius Therapeutics Inc 20.3%

Value ($000) $363,817 Shares 38,296,526 Est. Cost $24.00 Unrealized —

DNLI Denali Therapeutics Inc 7.8%

Value ($000) $139,016 Shares 7,980,263 Est. Cost $17.97 Unrealized -7.4%

KLDO Kaleido Biosciences Inc 4.9%

Value ($000) $87,151 Shares 17,360,710 Est. Cost $13.76 Unrealized -53.8%

— Seres Therapeutics Inc 4.2%

Value ($000) $74,423 Shares 21,571,764 Est. Cost $8.55 Unrealized —

— Evelo Biosciences Inc 4.1%

Value ($000) $74,027 Shares 18,233,403 Est. Cost $11.80 Unrealized —

— Axcella Health Inc 2.0%

Value ($000) $35,081 Shares 8,748,414 Est. Cost $9.31 Unrealized —

— Syros Pharmaceuticals Inc 1.1%

Value ($000) $20,305 Shares 2,938,494 Est. Cost $13.87 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
MRNA	Moderna Inc	50,871,524	$995,047	55.6%	$16.43	+7.9%	COM	60770K107
—	Rubius Therapeutics Inc	38,296,526	$363,817	20.3%	$24.00	—	COM	78116T103
DNLI	Denali Therapeutics Inc	7,980,263	$139,016	7.8%	$17.97	-7.4%	COM	24823R105
KLDO	Kaleido Biosciences Inc	17,360,710	$87,151	4.9%	$13.76	-53.8%	COM	483347100
—	Seres Therapeutics Inc	21,571,764	$74,423	4.2%	$8.55	—	COM	81750R102
—	Evelo Biosciences Inc	18,233,403	$74,027	4.1%	$11.80	—	COM	299734103
—	Axcella Health Inc	8,748,414	$35,081	2.0%	$9.31	—	COM	05454B105
—	Syros Pharmaceuticals Inc	2,938,494	$20,305	1.1%	$13.87	—	COM	87184Q107